GSK launches late-stage study of long-acting antibody for severe asthma
GSK’294 is designed to deliver long-acting suppression of IL-5 in severe eosinophilic asthma patients
Read More
Tag: IL-5
GSK’s Nucala approved for younger asthma patients
GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe eosinophilic asthma.
Read More
Data show ‘enduring’ benefits of GSK’s Nucala
GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.
Read More
NICE u-turn backs use of Teva’s asthma biologic
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
Read More
GSK tests mepolizumab for nasal polyps
GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
